Status and future directions of clinical trials in Parkinson's disease

Söderbom, Grażyna

doi:10.1016/bs.irn.2020.02.009

Cited by 7 publications

(1 citation statement)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD is known to be the second most common neurodegenerative disease after AD [ 5 ]. PD is considered a movement disorder caused by the accumulation of neuronal inclusions (Lewy Bodies) consisting of α-synuclein (aSyn) aggregates [ 6 , 7 ]. While both disorders are associated with aggregation that causes the onset of the disease, it is essential and beneficial to search for a potential treatment that could affect the beginning and progression of AD and PD.…”

Section: Introductionmentioning

confidence: 99%

Exploring the Formation of Polymers with Anti-Amyloid Properties within the 2′3′-Dihydroxyflavone Autoxidation Process

et al. 2022

View full text Add to dashboard Cite

Amyloid-β and α-synuclein aggregation into amyloid fibrils is linked to the onset and progression of Alzheimer’s and Parkinson’s diseases. While there are only a few disease-modifying drugs, it is essential to search for new, more effective ways to encounter these neurodegenerative diseases. Multiple research articles have shown that the autoxidation of flavone is a critical factor for activating the inhibitory potential against the protein aggregation. Despite this, the structure of the newly-formed inhibitors is unknown. In this research, we examined the autoxidation products of 2′,3′-dihydroxyflavone that were previously shown to possess one of the most prominent inhibitory effects against amyloid-β aggregation. Their analysis using HPLC suggested the formation of polymeric molecules that were isolated using a 3 kDa cut-off. These polymeric structures were indicated as the most potent inhibitors based on protein aggregation kinetics and AFM studies. This revelation was confirmed using MALDI-TOF and NMR. We also show that active molecules have a tendency to reduce the Amyloid-β and α-synuclein aggregates toxicity to SH-SY5Y cells.

show abstract

Section: Introductionmentioning

confidence: 99%